GlassScriptPhysician profile
Harsimrat Kaur
NPI 1760019806
$1,793.15
in general payments reported to CMS, 2019-2025
25 companies · $783 in 2025
The $783 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $247 · 2023: $479 · 2024: $162 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,404 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,404.12 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $339.48 | 2023-2025 | |
| Daiichi Sankyo INC. | $198.69 | 2023 | Enhertu |
| Pfizer INC. | $170.68 | 2023-2025 | |
| Amgen INC. | $167.76 | 2025 | Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $135.33 | 2022 | |
| Novo Nordisk INC | $114.97 | 2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $84.61 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $76.65 | 2025 | Airsupra, Breztri |
| Lilly USA, LLC | $71.51 | 2023-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $66.15 | 2025 | The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.25 | 2021 | |
| Dexcom, INC. | $39.46 | 2022-2025 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $33.33 | 2021 | |
| Axsome Therapeutics, INC. | $27.39 | 2024 | Auvelity |
| Abbott Laboratories | $26.06 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $25.13 | 2025 | |
| Sanofi Pasteur INC. | $24.43 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $22.82 | 2021 | |
| Phadia US INC. | $20.78 | 2024 | Immunocap |
| Nestle Healthcare Nutrition INC. | $19.95 | 2022 | |
| Alkermes, INC. | $18.82 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.62 | 2022 | |
| Cranial Technologies, INC | $15.20 | 2025 | Doc Band |
| Phathom Pharmaceuticals, INC. | $14.59 | 2025 | Voquezna |
| Seqirus USA INC | $13.49 | 2024 | Flucelvax, Fluad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harsimrat Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.